<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705627</url>
  </required_header>
  <id_info>
    <org_study_id>2007047</org_study_id>
    <nct_id>NCT00705627</nct_id>
  </id_info>
  <brief_title>A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter Trial Comparing Neoadjuvant Chemotherapy Followed by CCRT v.s. CCRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Center of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Shantou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Locoregionally advanced nasopharyngeal carcinoma (NPC)(stage III, IV in UICC 2002
      Classification) can be divided into two groups according to the risk of metastasis: high-risk
      metastasis group (T4 or N2-3) and low-risk metastasis group (T3N0-1). In low-risk metastasis
      group, concurrent chemoradiotherapy (CCRT) might decrease local recurrence and distance
      metastasis, which benefits overall survival. On the other hand, neoadjuvant chemotherapy is
      also associated with lower distance metastasis of advanced stage NPC. Nevertheless, CCRT
      alone or neoadjuvant chemotherapy alone leads to unsatisfactory results regarding to distance
      metastasis in patients with high-risk metastasis group. In this case, it is utmost important
      to investigate the new treatment combining neoadjuvant chemotherapy plus CCRT in order to
      improve overall survival of locoregionally advanced NPC with high-risk metastasis.

      In our study, in order to investigate the effect and adverse reaction of neoadjuvant
      chemotherapy plus CCRT on distance metastasis and locoregionally relapse, four hundred
      patients with high risk of distance metastasis will be randomly divided into two groups,
      comparing neoadjuvant chemotherapy (DDP+5FU) plus CCRT (DDP) and CCRT (DDP) alone. We aim to
      find out the best therapeutic regimen with lowest adverse reaction for NPCS with high risk of
      distance metastasis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distant metastasis free survival,disease free survival</measure>
    <time_frame>5-Yr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5-Yr</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: cisplatin. Patients in the control arm received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant chemotherapy plus concurrent chemoradiotherapy</intervention_name>
    <description>Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Neoadjuvant Chemotherapy Followed by CCRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed nasopharyngeal carcinoma, including WHO
             II or III

          -  Original clinical stage must be T4 or N2-3 （UICC 2002）

          -  Male and no pregnant female

          -  Age between 18-60

          -  WBC ≥4,000/mm3 and PLT ≥ 100,000/mm3

          -  With normal liver function test (ALT、AST≤2.5×ULN)

          -  With normal renal function test (Creatinine ≤ 1.5×ULN)

          -  Performance status scale ECOG grade 0，1

          -  Without radiotherapy or chemotherapy

          -  Patients must give signed informed consent

        Exclusion Criteria:

          -  Patients have evidence of relapse or distant metastasis

          -  The presence of uncontrolled life-threatening illness

          -  Receiving other ways of anti-cancer therapy

          -  Receiving radiotherapy or chemotherapy

          -  Investigator consider the patients can't finish the whole study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minghuang Hong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yet sen Cancer Center, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sumei Cao, Ph. D.</last_name>
    <phone>86-20-8734-5685</phone>
    <email>caosumei@mail/sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumei Cao, Ph. D</last_name>
      <phone>86-20-8734-5685</phone>
      <email>caosumei@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Minghuang Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <last_update_submitted>May 26, 2014</last_update_submitted>
  <last_update_submitted_qc>May 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hong Ming-huang</investigator_full_name>
    <investigator_title>the director of GCP</investigator_title>
  </responsible_party>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <keyword>randomized controlled clinical trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

